Stopping Retatrutide: What Happens When You Come Off

There is no published trial that follows people after they stop retatrutide — its Phase 2 study (NEJM 2023) ended treatment at 48 weeks with only a 4-week safety follow-up, and the Phase 3 TRIUMPH program is still running. So the honest answer to "what happens when I stop?" comes from two places: the withdrawal data for the closely related drug tirzepatide (the SURMOUNT-4 randomized withdrawal trial), and what retatrutide's own trial tells us about how the body behaves on the drug.

Both point to the same conclusion: GLP-class weight loss is maintained by the drug, not cured by it. When the medication stops, appetite returns and a substantial share of the lost weight comes back unless something else holds it in place. This page lays out the regain numbers, the symptoms people report on coming off, and the two realistic exit routes — stopping entirely versus transitioning to a maintenance agent.

How Much Weight Comes Back: The SURMOUNT-4 Evidence

Retatrutide has no published withdrawal trial. The best available evidence is SURMOUNT-4 (JAMA 2024), a Phase 3 randomized withdrawal study of tirzepatide — the dual agonist that shares two of retatrutide's three receptor targets (GLP-1 and GIP). Participants lost a mean 20.9% of body weight over a 36-week lead-in, then were randomized either to keep taking tirzepatide or to switch to placebo for 52 more weeks.

The takeaway: people who stopped regained on average 14% of their body weight within a year, and only about 1 in 6 held onto most of their loss. People who stayed on the drug kept losing. Withdrawing the medication did not freeze the result in place — it reversed a large part of it.

Retatrutide is expected to behave at least as dramatically on withdrawal, for a specific reason described below.

Why Retatrutide May Regain Faster Than Other GLP-Drugs

In the NEJM Phase 2 trial, retatrutide produced the largest weight loss reported for any anti-obesity drug in a study of a year or less — a mean 24.2% at the 12-mg dose by week 48. Critically, the trial investigators noted that the weight-loss curve had not yet reached a plateau when treatment was stopped at 48 weeks: participants were still actively losing weight when the drug was withdrawn.

That matters for stopping. A steeper, still-climbing weight-loss trajectory implies a larger appetite-suppression effect being held down by the drug — and therefore a larger rebound when that suppression is removed. Retatrutide's regain risk should be viewed as at least as high as tirzepatide's SURMOUNT-4 numbers, not lower, even though no head-to-head withdrawal data exists yet.

Symptoms People Report When Coming Off

Two categories of effect reverse when the drug clears (retatrutide's half-life is about 6 days, so it is largely gone within roughly a month):

• Appetite and "food noise" return. The hunger and craving suppression is a direct pharmacological effect. As drug levels fall, appetite returns — often described as food noise "switching back on." This is the mechanism behind the regain numbers above, not a failure of willpower.
• On-drug side effects fade. The dose-dependent heart-rate increase seen on retatrutide peaked at 24 weeks and then declined even while participants stayed on the drug; on stopping, the cardiovascular and GI effects of the medication resolve as it clears.

Community reports of mood changes (low mood, apathy, anhedonia) easing after cycling off, or of elevated resting heart rate and sleep disruption persisting at low doses, are anecdotal — they are not measured endpoints in any retatrutide trial and should be treated as individual experiences, not established effects.

Two Ways to Come Off

Option 1 — Stop entirely

Discontinuing without a replacement is the scenario SURMOUNT-4 measured directly: expect appetite to return and meaningful regain over the following year unless diet, training, and other supports are strong enough to substitute for the drug's appetite control. There is no evidence that any taper schedule prevents regain — regain is driven by the loss of appetite suppression, not by a withdrawal syndrome.

Option 2 — Transition to a maintenance agent

Some people move from retatrutide to a lower-intensity or maintenance drug (for example, a lower-dose GLP-1 or dual agonist) rather than stopping outright, on the logic that continued treatment maintains the loss — exactly what SURMOUNT-4's continued-drug arm showed. This is a clinical decision: there is no published protocol for switching off retatrutide onto a maintenance agent, and dose equivalence between these drugs is not established. (Our switching to retatrutide page covers the inbound direction — moving onto retatrutide from another GLP-1.)

Either route should be planned with a prescriber. The point of this page is the realistic expectation, not a recommendation.

Frequently Asked Questions

Sources

• Aronne, L.J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. Full text.
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389, 514–526. DOI: 10.1056/NEJMoa2301972.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA).

Do not start, stop, or change any medication based on this page without consulting a qualified healthcare provider. If you are considering coming off retatrutide or any weight-loss medication, talk to your doctor about how to do it safely.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.